Jane Street Group LLC Has $75,000 Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Jane Street Group LLC cut its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 32.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,870 shares of the company’s stock after selling 24,219 shares during the quarter. Jane Street Group LLC owned 0.10% of PMV Pharmaceuticals worth $75,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PMVP. Northern Trust Corp boosted its position in shares of PMV Pharmaceuticals by 23.2% during the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock worth $162,000 after acquiring an additional 20,190 shares in the last quarter. JPMorgan Chase & Co. raised its position in PMV Pharmaceuticals by 2,282.8% during the fourth quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company’s stock valued at $37,000 after purchasing an additional 23,559 shares in the last quarter. Aldebaran Capital LLC raised its position in PMV Pharmaceuticals by 14.6% during the fourth quarter. Aldebaran Capital LLC now owns 502,190 shares of the company’s stock valued at $758,000 after purchasing an additional 63,938 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in PMV Pharmaceuticals during the fourth quarter worth $673,000. Finally, BML Capital Management LLC boosted its holdings in shares of PMV Pharmaceuticals by 105.3% in the 4th quarter. BML Capital Management LLC now owns 3,466,684 shares of the company’s stock valued at $5,235,000 after purchasing an additional 1,777,912 shares in the last quarter. 90.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a report on Thursday, March 20th.

PMV Pharmaceuticals Trading Up 2.1%

PMVP opened at $0.97 on Monday. The company has a market cap of $50.39 million, a P/E ratio of -0.97 and a beta of 1.43. The company’s 50 day moving average is $0.94 and its 200-day moving average is $1.25. PMV Pharmaceuticals, Inc. has a 1-year low of $0.81 and a 1-year high of $1.83.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. On average, equities analysts forecast that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.